References
- Ames B.N., McCann J., Yamasaki E.: Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975, 31, 347–364.
- Ballet J.J., Morin A., Schmitt C., Agrapart M.: Effect of isoprinosine on in vitro proliferative responses of human lymphocytes stimulated by antigen. Int J Immunopharmacol 1982, 4, 151–157.
- Campoli-Richards D.M., Sorkin E.M., Heel R.C.: Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986, 32, 383–424.
- Fang J.L., Beland F.A.: Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci 2009, 111, 120–130.
- Gutierrez J., Issacson R.S., Koppel B.S.: Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol 2010, 52, 901–907.
- Hennessy K.J., Blecha F., Pollmann D.S., Kluber E.F.: Isoprinosine and levamisole immunostimulation in artificially reared neonatal pigs. Am J Vet Res 1987, 48, 477–480.
- OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 471: Bacterial Reverse Mutation Test.
- OECD Guideline 487: In Vitro Mammalian Cell Micronucleus Test.
- http://www.eurofins.com/biopharma-services/discovery/services/adme-tox/in-vitro-toxicity/genotoxicity/ames-test/.
- ICH guideline S2 (R1) on genotoxicity testing and data interpretation for pharmaceuticals intended for human use Step 5, EMA/CHMP/ICH/126642/200.
- Lasek W., Janyst M., Wolny R. Zapała Ł., Bocian K., Drela N.: Immuno-modulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm 2015, 65, 171–180.
- Majewska A., Lasek W., Młynarczyk G.: Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), enteroviruses (CA16, EV71), and adenoviruses (HAdV-2, HAdV-5) in vitro Med Dosw Mikrobiol 2015, 67, 107–113.
- Maron D.M., Ames B.N.: Revised methods for the Salmonella mutagenicity test. Mutat Res 1983, 113, 173–215.
- Meek B., Doull J.: Pragmatic challenges for the vision of toxicity testing in the 21st century in a regulatory context: another Ames test? ...or a new edition of “the Red Book”? Toxicol Sci 2009, 108, 19–21.
- Nakamura T., Miyasaka N., Pope R.M., Talal N., Russell I.J.: Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases. Clin Exp Immunol 1983, 52, 67–74.
- Ohnishi H., Kosuzume H., Inaba H., Okura M., Morita Y., Mochizuki H., Suzuki Y.: Mechanism of host defence suppression induced by viral infection: mode of action of inosiplex as an antiviral agent. Infect Immun 1982, 38, 243–250.
- Ohnishi H., Kosuzume H., Inaba H., Ohkura M., Shimada S., Suzuki Y.: The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections. Int J Immunopharmacol 1983, 5, 181–196.
- Osidak L.V., Obraztsova E.V.: The results of studying of inclusion of inosine pranobex into the therapy of acute respiratory viral infections in children (in Russian). Lechaschiy Vrach 2012, 10, 1–4.
- Pedersen C., Sandström E., Petersen C.S., Norkrans G., Gersto J., Karlsson A., Christensen K.C., Håkanson C., Pehrson P., Nielsen J.O., Jucrgensen H.J.: Scandinavian Isoprinosine Study Group: The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990, 322, 1757–1763.
- Petrova M., Jelev D., Ivanova A., Krastev Z.: Isoprinosine affects serum cytokine levels in healthy adults. J Interferon Cytokine Res 2010, 30, 223–228.
- Roe A.L., Snawder J.E., Benson R.W., Roberts D.W., Casciano D.A.: HepG2cells: an in vitro model for P450-dependent metabolism of acetaminophen. Biochem Biophys Res Commun 1993, 190, 15–19.
- Schoonen W.G., de Roos J.A., Westerink W.M., Débiton E.: Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol in Vitro 2005, 19, 491–503.
- Simon L.N., Glasky A.J.: Isoprinosine: an overview. Cancer Treat Rep 1978, 62, 1963–1969.
- Terpilowska S., Siwicki A.K.: Interactions between chromium(III) and iron(III), molybdenum(III) or nickel(II): Cytotoxicity, genotoxicity, and mutagenicity studies. Chemosphere 2018, 201, 780–789.
- Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F.: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000, 35, 206–221.
- Tsang H., Fudenberg H., Gnagy M.J.: Restoration of immune response of aging hamsters by treatment with Isoprinosine. J Clin Invest 1983, 71, 1750–1755.
- Wybran J., Faman J.P., Gortz R.: Inosiplex (Isoprinosine): a review of its immunological and clinical effects in disease. Adv Pharmacol Ther 1982, 6, 123–131.
- Wybran J., Govaerts A., Appleboom, T.: Inosiplex, a stimulating agent for normal human T cells and human leukocytes. J Immunol 1978, 121, 1184–1187.
- Yakupova R.S., Skachkova M.A., Choloyan S.B., Karpova E.G.: Efficacy of immunomodulators in children with respiratory diseases in environmentally poor areas. Gig Sanit 2012, 3, 33–34.